ReNerve inks deal to expand nerve-repair product in Hong Kong and Macau

ReNerve signs exclusive distribution deal with Accession Medical Supplies for sales and marketing of NervAlign in Hong Kong and Macau

The NervAlign Nerve Cuff is an FDA-cleared product for use on damaged or transected nerves

ReNerve has applied for regulatory approval in Hong Kong, which it anticipates being granted in mid-2025

Special Report: Newly listed nerve-repair company ReNerve has inked an exclusive distribution partnership with Accession Medical Supplies for the sales and marketing of its NervAlign Nerve Cuff product in Hong Kong and Macau.

As part of the agreement the leading supplier of medical devices in Hong Kong will purchase the ReNerve (ASX:RNV) NervAlign product range as a wholesaler with the two companies working together to gain regulatory approval in Hong Kong.

The NervAlign Nerve Cuff is an FDA-approved device designed to repair damaged or cut nerves with no gaps between the nerve ends or when gaps can be closed by bending the surrounding area.

ReNerve has submitted an application for regulatory approval in Hong Kong and anticipates approval to be granted in mid-2025.

Opening doors to Hong Kong, China and Taiwan

ReNerve noted that Accession is a leading supplier of medical devices in Hong Kong, China and Taiwan.

Accession specialises in sourcing and distributing innovative medical devices and pharmaceutical products by partnering with world-class companies that share its vision for innovation and improving patient outcomes.

ReNerve said it was attracted to teaming with Accession because the medical-devices supplier has appropriate warehousing, distribution, sales and marketing capacities in the region, as well as key relationships.

Combined, Hong Kong and Macau is a concentrated market, which enables Accession to efficiently target hospitals in the regions.

ReNerve noted Accession has forged relationships with hospitals and surgeons in the region, which the companies can leverage to generate initial and ongoing sales of NervAlign.

A huge benefit of entering this market is that it serves as a gateway to the Guangdong-Hong Kong-Macau Greater Bay Area, which has a population of more than 86 million.

‘Pivotal step in ReNerve’s growth strategy’

ReNerve made its ASX debut on November 26 and is targeting the global nerve-repair biomaterials market, which it said was valued at US$1.96 billion in 2024 and projected to grow at a CAGR of 17.8% from 2024 to 2031 to US$6.19 billion.

ReNerve CEO Dr Julian Chick said the collaboration with Accession not only accelerated its international expansion but also positioned ReNerve to tap into significant growth opportunities in the broader Greater Bay Area

“The exclusive partnership with Accession represents a pivotal step forward in ReNerve’s growth strategy,” he said.

“By leveraging Accession’s extensive local expertise and established relationships with key hospitals and surgeons in Hong Kong and Macau, we are confident in our ability to successfully introduce and expand the reach of the NervAlign Nerve Cuff in this dynamic market.

“As we continue to advance our innovative solutions for nerve repair, this partnership underscores our commitment to improving patient outcomes and driving sustainable value for our stakeholders.”

This article was developed in collaboration with ReNerve, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.